AstraZeneca announced that a durvalumab (Imfinzi)-based perioperative regimen has been recommended by the EMA Committee for ...

The Phase III MATTERHORN trial demonstrated that Imfinzi (durvalumab) plus FLOT chemotherapy significantly improved ...

The CheckMate -816 trial shows nivolumab plus platinum-doublet chemotherapy significantly improves overall survival in ...

The FDA has approved Tislelizumab (Tevimbra) plus platinum-based chemotherapy as a first-line treatment for adult patients ...

KEYTRUDA (pembrolizumab) plus standard care for resectable locally advanced head and neck squamous cell carcinoma receives ...

The early findings from the SERENA-6 trial indicate that the investigational oral SERD camizestrant provides a “highly statistically significant and clinically meaningful” improvement in ...

The European Medicines Agency (EMA) committee (CHMP) has recommended approving trastuzumab deruxtecan (Enhertu), a ...

Regeneron Pharmaceuticals, announced that FDA accepted its resubmitted Biologics License Application for odronextamab, a ...

The innovative GO chip, developed at the University of Michigan, represents a significant leap in lung cancer treatment by ...

In this interview with Dr. Maria de Miguel, we explore the transformative potential of Antibody-Drug Conjugates (ADCs) in oncology. Dr. de Miguel shares insights on Temab-A, a c-Met-targeted ADC ...

Today, we are hosting Dr. Raza Bokhari, CEO at Medicus Pharma, to explore a breakthrough innovation in skin cancer ...